Efficacy News and Research

RSS

Russian-trained microbiologist recommends tips for consumers to achieve effective results from probiotics

With the European Union poised to regulate probiotics, and with probiotic supplement sales increasing dramatically in the United States, Americans need to know what they're buying, and how these products can affect their health.

20 Nov 2010

USC Norris designated Phase I Clinical Trial Center of Excellence

The USC Norris Comprehensive Cancer Center (USC Norris) has been designated a Phase I Clinical Trial Center of Excellence by global pharmaceutical company Bristol-Myers Squibb Company. The collaboration will bring a number of new phase I clinical trials to USC Norris, and will enable the cancer center's clinical and basic scientists to provide guidance in early phase drug development and trial design.

20 Nov 2010

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

Thirty-four percent of malaria-endemic countries are complying with WHO guidelines to monitor artemisinin resistance within their borders, the agency said in a report on Thursday, CBS News reports (11/18). Reuters reports that artemisinin "is the best drug available against malaria, especially when used in artemisinin combination therapy (ACT), which combines it with other drugs that finish off the [malaria] parasite" (Nebehay, 11/18).

20 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA has also informed the generic manufacturers of propoxyphene-containing products of Xanodyne's decision and requested that they voluntarily remove their products as well.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Recent releases in Global Health

New This Week In The Kaiser Global Health Policy Tracker: The President's Malaria Initiative announced a new focus country and USAID released a new fact sheet on the agency's reform initiative. Kaiser's Policy Tracker provides a timely single reference point for the latest information on congressional and administration action on global health.

20 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

Personalised medicine could help develop effective treatments for serious diseases

Personalised medicine is a field that holds a lot of promise as a provider of practices and technology that could help develop more effective treatments for serious diseases such as cancer. Personalised medicine involves tailoring treatment according to the genetic profile and molecular makeup of each patient.

19 Nov 2010

New direct labeling system for oocytes, embryos

Researchers from the Department of Cell Biology, Physiology and Immunology at Universitat Autònoma de Barcelona (UAB), in collaboration with researchers from the Institute of Microelectronics of Barcelona (IMB-CNM) of the Spanish National Research Council (CSIC), have developed an identification system for oocytes and embryos in which each can be individually tagged using silicone barcodes.

19 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

National monitoring essential for preventing emergence of malaria drug resistance

WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

Efficacy News and Research

Russian-trained microbiologist recommends tips for consumers to achieve effective results from probiotics

USC Norris designated Phase I Clinical Trial Center of Excellence

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Recent releases in Global Health

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

ACE-041 drug may provide new option to treat cancer

Personalised medicine could help develop effective treatments for serious diseases

New direct labeling system for oocytes, embryos

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

National monitoring essential for preventing emergence of malaria drug resistance

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

OXiGENE updates data on FALCON trial for non-small cell lung cancer

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News